Biosensors (Feb 2022)

Accuracy Assessment of the GlucoMen<sup>®</sup> Day CGM System in Individuals with Type 1 Diabetes: A Pilot Study

  • Daniel A. Hochfellner,
  • Amra Simic,
  • Marlene T. Taucher,
  • Lea S. Sailer,
  • Julia Kopanz,
  • Tina Pöttler,
  • Julia K. Mader

DOI
https://doi.org/10.3390/bios12020106
Journal volume & issue
Vol. 12, no. 2
p. 106

Abstract

Read online

The aim of this study was to evaluate the accuracy and usability of a novel continuous glucose monitoring (CGM) system designed for needle-free insertion and reduced environmental impact. We assessed the sensor performance of two GlucoMen® Day CGM systems worn simultaneously by eight participants with type 1 diabetes. Self-monitoring of blood glucose (SMBG) was performed regularly over 14 days at home. Participants underwent two standardized, 5-h meal challenges at the research center with frequent plasma glucose (PG) measurements using a laboratory reference (YSI) instrument. When comparing CGM to PG, the overall mean absolute relative difference (MARD) was 9.7 [2.6–14.6]%. The overall MARD for CGM vs. SMBG was 13.1 [3.5–18.6]%. The consensus error grid (CEG) analysis showed 98% of both CGM/PG and CGM/SMBG pairs in the clinically acceptable zones A and B. The analysis confirmed that GlucoMen® Day CGM meets the clinical requirements for state-of-the-art CGM. In addition, the needle-free insertion technology is well tolerated by users and reduces medical waste compared to conventional CGM systems.

Keywords